Clinical trials: Sirolimus
Aging
RESTOR: PK/PD mTORi Inhibition in Older Adults
As people get older, there are changes in their cells and tissues that may affect their ability to function. This can lead to increased death and age-associated disorders, like heart disease, cancer, and Alzheimer's disease.
- Trial name
- RESTOR (NCT06658093)
- Testing
- Rapamycin, Everolimus
- Where
- United States
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Hepatic Insufficiency
Pharmacokinetics of Everolimus in Subjects With Hepatic Insufficiency
This clinical pharmacology research study will assess the safety and pharmacokinetics of the drug everolimus in patients with impaired hepatic function as compared to healthy volunteers.
- Trial name
- NCT00968591
- Testing
- Everolimus
- Where
- 3 sites in Germany, Russia and 1 more
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Epilepsy
Application of Novel Diagnostic and Therapeutical Methods in Epilepsy and Neurodevelopmental Abnormalities in Children.
Epilepsy affects 1% of the world's population and 6 million people in Europe. The estimated total cost of €20 billion in Europe in 2014 makes epilepsy a significant socioeconomic burden.
- Trial name
- EPIMARKER (NCT03486366)
- Testing
- non interventional trial
- Where
- Poland
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Medical University of Warsaw
Genetic Predisposition to Disease, Healthy Volunteer
Effects of Sirolimus on Asymptomatic ApoE4 Carriers
Alzheimer's disease is a devastating neurodegenerative disease characterized by accumulation of clumps (also called plaques) and bundles of fibers (also called tangles) in the brain, for which there is currently no cure.
- Conditions
- Genetic Predisposition to Disease, Healthy Volunteer, APOE-4 Positive
- Trial name
- NCT07728175
- Testing
- Sirolimus (rapamycin)
- Where
- United States
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Pharmacokinetics
Randomized Crossover of SVG101(Dispersible Tab. of Everolimus) and Afinitor 5mg in Healthy Adults
The purpose of this study is to determine the pharmacokinetics and safety of SVG101 (dispersible tab. of everolimus) in healthy volunteers compared to Afinitor tab. after oral administration.
- Trial name
- NCT05490095
- Testing
- SVG101 (T), Afinitor (R)
- Where
- South Korea
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Sovargen
B-cell Lymphoma Refractory
Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma
This is an open label phase I study of Inotuzumab Ozogamicin, an antibody-targeted intravenous chemotherapy agent composed of a CD22-targeted antibody linked to calicheamicin, in combination with the mammalian target of rapamycin…
- Trial name
- IOSI-LND-001 (NCT01535989)
- Testing
- Inotuzumab Ozogamicin, Temsirolimus
- Where
- 3 sites in Switzerland
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Cristiana Sessa
Peripheral T-cell Lymphomas, Lymphoproliferative Disorders
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
Background: Lymphoma is a type of blood cancer. Blood cell transplant can cure some people with lymphoma. Researchers want to see if they can limit the complications transplant can cause.
- Conditions
- Peripheral T-cell Lymphomas, Lymphoproliferative Disorders, Immune System Diseases
- Trial name
- NCT03922724
- Testing
- ATL-RIC, mRIC, allo HCT
- Where
- 2 sites in United States
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Healthy, Osteopenia
Resistance Training and Rapamycin to Enhance Bone Formation in Postmenopausal Women
The aim of the present clinical trial is to examine the effects of everolimus, resistance training, or their combination on bone and muscle health formation in elderly women aged 60-75 years.
- Conditions
- Healthy, Osteopenia, Osteoporosis Risk
- Trial name
- StrongBone (NCT07191353)
- Testing
- Everolimus, Resistance training
- Where
- 2 sites in Denmark
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- Odense University Hospital
Liver Cancer
Sirolimus and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
RATIONALE: Sirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Trial name
- NCT00467194
- Testing
- Rapamycin, Bevacizumab
- Where
- 2 sites in Singapore
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- National Cancer Centre, Singapore
Liver Transplant Rejection, Immunosuppression
Immune Tolerance and Alloreactivity in Liver Transplant Recipients on Different Monotherapy Immunosuppressive Agents
This study is being done with the purpose of trying to understand if and why transplant recipients may develop tolerance to their transplanted organ.
- Trial name
- NCT01678937
- Testing
- Blood Draw - Rapamycin, Blood Draw from Control Subjects, Blood Draw - CyA
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Advanced Renal Cell Carcinoma
Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)
The study consists of two parts, the first part is a randomized, open-label, active-controlled study to evaluate the efficacy and safety of fruquintinib in combination with sintilimab versus axitinib or everolimus monotherapy as…
- Trial name
- NCT05522231
- Testing
- fruquintinib+sintilimab, axitinib / everolimus, fruquintinib
- Where
- 48 sites in China
- Volunteers
- 265 people, healthy volunteers welcome
- Sponsor
- Hutchmed
Graves Ophthalmopathy
Rapamycin Plus Methylprednisolone Versus Methylprednisolone Alone in Active, Moderate-to-severe Graves' Orbitopathy.
This study is a randomized, controlled, multi-center clinical study, the purpose is to evaluate the efficacy and safety of rapamycin combined with methylprednisolone in the treatment of moderate to severe active GO.
- Trial name
- NCT05532072
- Testing
- Rapamycin, Methylprednisolone
- Where
- China
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Port-Wine Stain
Treatment of Port Wine Stains Using Pulsed Dye Laser, Erbium Yag Laser and Topical Sirolimus
The purpose of this study is to improve the therapeutic outcome of laser therapy for port wine stains by using a combination treatment of the pulsed dye laser (PDL), erbium yag laser and topical sirolimus.
- Trial name
- NCT02214706
- Testing
- Sirolimus, Erbium yag laser, Pulsed Dye Laser
- Where
- Netherlands
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Erasmus Medical Center
Kidney Transplant, Immunology
Protective Immunity Project 02
Influenza (Flu) vaccine is recommended for kidney transplant patients who are at least 6 months post-transplant. The influenza vaccine stimulates the immune system to builds protective antibodies against the flu virus.
- Conditions
- Kidney Transplant, Immunology, Immunosuppression
- Trial name
- PIP-02 (NCT00833651)
- Where
- United States
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Emory University
Neoplastic Syndrome, Non-melanomatous Skin Cancer
Topical Sirolimus in Patients With Basal Cell Nevus Syndrome and in Healthy Participants
RATIONALE: Studying samples of blood and tissue from patients with basal cell nevus syndrome and from healthy participants in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers…
- Trial name
- NCT00433485
- Testing
- sirolimus, comparative genomic hybridization, gene expression analysis
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Yale University
Healthy
Bioavailability Study of Sirolimus Tablets 2 mg Under Fasting Condition
This study is to assess the Sirolimus Tablets 2 mg of Dr. Reddy's Laboratories Limited, India and Rapamune® (Sirolimus) tablets 2 mg of Wyeth Laboratories, Philadelphia in healthy, adult,human subjects under Fasting conditions.
- Trial name
- NCT02296749
- Testing
- Sirolimus
- Where
- India
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Coronary Artery Disease
A Trial of Bare Metal Stent - Cobalt Chromium Versus Stent Coating With Sirolimus
The objective of this study is to evaluate the security issues and efficacy of coronary stenting Cobalt Chrome covered with sirolimus-eluting Cobalt Chrome platform in patients with coronary artery lesion.
- Trial name
- INSPIRON (NCT01093391)
- Testing
- DRUG ELUTING STENT, BARE METAL STENT
- Where
- 4 sites in Brazil
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Scitech Produtos Medicos SA
Aging
The Role of Sirolimus in Preventing Functional Decline in Older Adults
Aging is associated with progressive impairment of tissue and organ function, resulting in increased susceptibility to chronic disease, frailty and disability.
- Trial name
- NCT05237687
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Irina Timofte
Tuberous Sclerosis, Neurofibromatoses
Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)
This study is a prospective, randomized, double-blind, placebo-controlled evaluation of the safety of a topically applied formulation of rapamycin to cutaneous fibromatous lesions in subjects with Tuberous Sclerosis Complex (TSC)…
- Conditions
- Tuberous Sclerosis, Neurofibromatoses, Angiofibroma, Neurofibroma
- Trial name
- NCT01031901
- Testing
- Skincerity, Skincerity plus sirolimus/rapamycin, Skinercity plus sirolimus/rapamycin
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Aging
Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study
This is a randomized, placebo-controlled trial into the safety and efficacy in reducing clinical measures of aging in an older adult population.
- Trial name
- PEARL (NCT04488601)
- Testing
- Rapamycin
- Where
- United States
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- AgelessRx